287 related articles for article (PubMed ID: 25194178)
21. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
Reeves HL; Zaki MY; Day CP
Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078
[TBL] [Abstract][Full Text] [Related]
22. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
Xin FZ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
[TBL] [Abstract][Full Text] [Related]
23. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
[TBL] [Abstract][Full Text] [Related]
25. Non-alcoholic fatty liver disease: A sign of systemic disease.
Reccia I; Kumar J; Akladios C; Virdis F; Pai M; Habib N; Spalding D
Metabolism; 2017 Jul; 72():94-108. PubMed ID: 28641788
[TBL] [Abstract][Full Text] [Related]
26. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).
Saokaew S; Kanchanasuwan S; Apisarnthanarak P; Charoensak A; Charatcharoenwitthaya P; Phisalprapa P; Chaiyakunapruk N
Liver Int; 2017 Oct; 37(10):1535-1543. PubMed ID: 28294515
[TBL] [Abstract][Full Text] [Related]
27. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
29. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
[TBL] [Abstract][Full Text] [Related]
30. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
Fan JG
J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
[TBL] [Abstract][Full Text] [Related]
31. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Byrne CD
Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
[TBL] [Abstract][Full Text] [Related]
32. Link of obesity and gastrointestinal cancer: crossroad of inflammation and oxidative stress.
Yang XD; Jiang S; Wang G; Zhang R; Zhang J; Zhu JS
J Biol Regul Homeost Agents; 2015; 29(4):755-60. PubMed ID: 26753635
[TBL] [Abstract][Full Text] [Related]
33. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
Scorletti E; Byrne CD
Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
35. [Research on the natural history of non-alcoholic fatty liver disease should be taken seriously].
Zhao ZH; Liu XL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):81-84. PubMed ID: 28297791
[TBL] [Abstract][Full Text] [Related]
36. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
Agosti P; Sabbà C; Mazzocca A
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty pancreas disease.
Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
[TBL] [Abstract][Full Text] [Related]
38. Obesity and metabolic syndrome: pathological effects on the gastrointestinal tract.
Feakins RM
Histopathology; 2016 Apr; 68(5):630-40. PubMed ID: 26599607
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease: defining a common problem.
Gasbarrini G; Vero V; Miele L; Forgione A; Hernandez AP; Greco AV; Gasbarrini A; Grieco A
Eur Rev Med Pharmacol Sci; 2005; 9(5):253-9. PubMed ID: 16231586
[TBL] [Abstract][Full Text] [Related]
40. [Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease].
Hagymási K; Reismann P; Rácz K; Tulassay Z
Orv Hetil; 2009 Nov; 150(48):2173-81. PubMed ID: 19923096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
